Disease-a-month : DM
March 1, 2025
Andrew M Farrar, Isabelle H Nordstrom, Kaitlyn Shelley et al.
7 citations
3,4-methylenedioxymethamphetamine (MDMA; commonly referred to as "ecstasy" or "molly") is a substituted amphetamine drug that is used recreationally for its acute psychoactive effects, including euphoria and increased energy, as well as prosocial effects such as increased empathy and feelings of closeness with others. Acute adverse effects can include hyperthermia, dehydration, bruxism, and...
The British Journal of Psychiatry
February 26, 2025
Ziad Saade, Alex S Keuroghlian
2 citations
This article explores the potential of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy to enhance exposure and response prevention in obsessive-compulsive disorder treatment. We discuss the mechanisms of MDMA, including fear extinction, psychological flexibility, and empathogenic effects that may improve adherence and efficacy, as well as highlighting important safety considerations...
CPT: Pharmacometrics & Systems Pharmacology
February 1, 2025
Marilyn A. Huestis, William B Smith, Cathrine Leonowens et al.
3 citations
Midomafetamine (3,4-methylenedioxymethamphetamine [MDMA]) is under the U.S. Food and Drug Administration review for treatment of post-traumatic stress disorder in adults. MDMA is metabolized by CYP2D6 and is a strong inhibitor of CYP2D6, as well as a weak inhibitor of renal transporters MATE1, OCT1, and OCT2. A pharmacokinetic phase I study was conducted to evaluate the effects of food on MDMA...
Contemporary Clinical Trials Communications
February 1, 2025
Jessica L Maples-Keller, Boadie W Dunlop, Barbara O Rothbaum
5 citations
This article describes the rationale and the specific methods for an open label pilot trial of 100 mg MDMA in combination with massed exposure therapy for PTSD, a treatment which involves daily exposure therapy sessions for two weeks which has found to be effective. We review the need for novel PTSD treatments and the existing research on MDMA-assisted therapy, and then describe the rationale...
Current Psychiatry Reports
February 1, 2025
Jamarie Geller, Eric Whitney
3 citations
There is a mental health crisis affecting youth, and the utility of existing treatments is often limited by lack of effectiveness and tolerability. The aim of this review is to report on outcomes of clinical trials for psilocybin-assisted psychotherapy for adults with depression and MDMA-assisted psychotherapy for adults with post-traumatic stress disorder (PTSD) and discuss recommendations for...
CNS Spectrums
January 30, 2025
Steve O'Brien, David Nutt
5 citations
This chapter explores the complex and controversial path of MDMA-assisted therapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) and other behavioral disorders. It covers MDMA's history from research to recreation to medicine, the pivotal trials, and the challenges faced by researchers. Despite recent setbacks for the clinical application of MDMA, the chapter argues that it holds...
Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention
January 21, 2025
Jennifer L. Schumann, Matthew Di Rago, Noel Woodford et al.
1 citation
Driving under the influence of alcohol and other drugs contributes significantly to road traffic crashes worldwide. This study explored trends of alcohol, methylamphetamine (MA), 3,4-methylenedioxy-N-methylamphetamine (MDMA) and Δ9-tetrahydrocannabinol (THC), in road crashes from 2010 to 2019 in Victoria, Australia. We conducted a cross-sectional analysis using data from the Victorian Institute...
Journal of Education, Health and Sport
January 14, 2025
Wiktoria Podlasiewicz, Paweł Siudziński, Mateusz Łyko et al.
MDMA or 3,4- methylenedioxymethamphetamine is a psychoactive substance, exhibiting mild hallucinogenic properties, that became widely known as a recreational party drug. However, its ability in helping individuals access deeply rooted emotions has prompted significant interest in its potential applications within clinical practice. MDMA’s mechanism of action involves increasing the release of...
The American Journal of Bioethics
January 13, 2025
Jamie Beachy, Willa Hall, Chantelle Thomas et al.
2 citations
As research therapists with hundreds of hours of clinical experience supporting adults with PTSD in Phase 3 trials of MDMA assisted-therapy (MAT), we appreciate the opportunity to respond to this s...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
January 10, 2025
Dan Xu, Akifumi Eguchi, Rumi Murayama et al.
4 citations
3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy) is a widely abused recreational drug that has also gained interest for potential clinical applications in mental health. With the growing recognition of gut microbiota's role in mental health, this study examined whether repeated oral MDMA administration could affect gut microbiota in the small intestine, cecum, and colon of male rats. Repeated...